These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 18652661)
21. Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo. Ju YH; Doerge DR; Woodling KA; Hartman JA; Kwak J; Helferich WG Carcinogenesis; 2008 Nov; 29(11):2162-8. PubMed ID: 18632754 [TBL] [Abstract][Full Text] [Related]
22. Recent developments in steroidal and nonsteroidal aromatase inhibitors for the chemoprevention of estrogen-dependent breast cancer. Ahmad I; Shagufta Eur J Med Chem; 2015 Sep; 102():375-86. PubMed ID: 26301554 [TBL] [Abstract][Full Text] [Related]
23. Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity. Kazi A; Goloubeva O; Schech A; Yu S; Sabnis GJ J Steroid Biochem Mol Biol; 2020 Sep; 202():105697. PubMed ID: 32461092 [TBL] [Abstract][Full Text] [Related]
24. Anti-tumor effects of letrozole. Miller WR; Anderson TJ; Dixon JM Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345 [TBL] [Abstract][Full Text] [Related]
25. Estradiol as an anti-aromatase agent in human breast cancer cells. Pasqualini JR; Chetrite GS J Steroid Biochem Mol Biol; 2006 Jan; 98(1):12-7. PubMed ID: 16413774 [TBL] [Abstract][Full Text] [Related]
26. Aromatase inhibitors in the treatment of breast cancer. Brueggemeier RW; Hackett JC; Diaz-Cruz ES Endocr Rev; 2005 May; 26(3):331-45. PubMed ID: 15814851 [TBL] [Abstract][Full Text] [Related]
27. Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line. Sonne-Hansen K; Lykkesfeldt AE J Steroid Biochem Mol Biol; 2005 Jan; 93(1):25-34. PubMed ID: 15748829 [TBL] [Abstract][Full Text] [Related]
28. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model. Long BJ; Jelovac D; Thiantanawat A; Brodie AM Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443 [TBL] [Abstract][Full Text] [Related]
29. Exemestane metabolites: Synthesis, stereochemical elucidation, biochemical activity and anti-proliferative effects in a hormone-dependent breast cancer cell line. Varela CL; Amaral C; Tavares da Silva E; Lopes A; Correia-da-Silva G; Carvalho RA; Costa SC; Roleira FM; Teixeira N Eur J Med Chem; 2014 Nov; 87():336-45. PubMed ID: 25277066 [TBL] [Abstract][Full Text] [Related]
30. Unveiling the mechanism of action behind the anti-cancer properties of cannabinoids in ER Amaral C; Trouille FM; Almeida CF; Correia-da-Silva G; Teixeira N J Steroid Biochem Mol Biol; 2021 Jun; 210():105876. PubMed ID: 33722705 [TBL] [Abstract][Full Text] [Related]
31. Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells. Belosay A; Brodie AM; Njar VC Cancer Res; 2006 Dec; 66(23):11485-93. PubMed ID: 17145897 [TBL] [Abstract][Full Text] [Related]
32. Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts. Andreucci E; Francica P; Fearns A; Martin LA; Chiarugi P; Isacke CM; Morandi A Oncotarget; 2016 Dec; 7(49):80543-80553. PubMed ID: 27602955 [TBL] [Abstract][Full Text] [Related]
33. Biochemical and biological characterization of a novel anti-aromatase coumarin derivative. Chen S; Cho M; Karlsberg K; Zhou D; Yuan YC J Biol Chem; 2004 Nov; 279(46):48071-8. PubMed ID: 15358790 [TBL] [Abstract][Full Text] [Related]
34. AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies. Wong C; Wang X; Smith D; Reddy K; Chen S Breast Cancer Res Treat; 2012 Jul; 134(2):671-81. PubMed ID: 22706627 [TBL] [Abstract][Full Text] [Related]
35. Aromatase Inhibitors for the Treatment of Breast Cancer: A Journey from the Scratch. Ratre P; Mishra K; Dubey A; Vyas A; Jain A; Thareja S Anticancer Agents Med Chem; 2020; 20(17):1994-2004. PubMed ID: 32593281 [TBL] [Abstract][Full Text] [Related]
36. Possible role of the aromatase-independent steroid metabolism pathways in hormone responsive primary breast cancers. Hanamura T; Niwa T; Gohno T; Kurosumi M; Takei H; Yamaguchi Y; Ito K; Hayashi S Breast Cancer Res Treat; 2014 Jan; 143(1):69-80. PubMed ID: 24292869 [TBL] [Abstract][Full Text] [Related]
37. The potential therapeutic benefits of vitamin D in the treatment of estrogen receptor positive breast cancer. Krishnan AV; Swami S; Feldman D Steroids; 2012 Sep; 77(11):1107-12. PubMed ID: 22801352 [TBL] [Abstract][Full Text] [Related]
38. Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer. Lønning PE Breast Cancer Res Treat; 1998; 49 Suppl 1():S45-52; discussion S73-7. PubMed ID: 9797017 [TBL] [Abstract][Full Text] [Related]
39. Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells. Lui A; New J; Ogony J; Thomas S; Lewis-Wambi J BMC Cancer; 2016 Jul; 16():487. PubMed ID: 27421652 [TBL] [Abstract][Full Text] [Related]
40. Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer. Brodie A; Lu Q; Liu Y; Long B; Wang JP; Yue W Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):36-40. PubMed ID: 9556790 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]